Connect with us

News

European healthcare professionals react to new ultrasound technology

Published

on

European ultrasound specialists have responded to the launch of an advanced ultrasound system by international health technology provider Mindray.

The Resona A20, unveiled in Naples late last year at the 35th congress of the European Federation of Ultrasound Societies in Medicine and Biology, was developed by Mindray to allow healthcare professionals to have a “deeper comprehension of the human body”, and to enable early detection of illness with new levels of confidence.

It is the first premium ultrasound system to be developed by the company.

‘The highest level of confidence for complex cases’

Professor Vito Cantisani, president of the European Federation of Societies for Ultrasound in Medicine and Biology, remarked he was “positively impressed” with the new technology as one of the world’s first users. “I found this new equipment very useful to evaluate deeply complicated cases,” he said. “The Resona A20 brings the best image quality for the highest level of confidence.”

Professor Cantisani, who is also chairman of integrated advanced imaging at University Sapienza, Rome, remarked how software in the Resona A20 supported multi-parametric evaluation, helping to deliver “a comprehensive evaluation of my patients”. “We are entering a new era,” he said.

He pointed out that one significant improvement is the multi-parametric liver study, helping to comprehensively study any pathology. He added that the technology enables all requested information to be displayed in real-time in one shot.

“The A20 smart thyroid tool gives automatic real-time lesion detection, which helps to be fast and precise,” Professor Cantisani added.

“HD Scope+is very useful because it increases the level of confidence, enhancing the border delineation, the eco-structures, the presence of calcification of the lesion that I study, such as breast and thyroid lesions, where it is really important to depict clearly and properly any of those features.”

Microvasculature study functionality was also described as important

A ‘slow flow’ often suggests that there might be a problem with the small blood vessels. Professor Cantisani said: “The ultra micro angiography provides a very high sensitive depiction of the slow flow.”

The new technology is expected to support daily clinical activity, research, and education, with the potential to enhance the role of ultrasound in the diagnostic imaging landscape.

Dynamic tumour information, and new pathways

The new high frame rate of the Resona A20 could make a “major difference” for healthcare professionals in delivering a correct diagnosis quickly for kidney, liver and oncology patients, and could help to transform clinical pathways, according to Prof Dirk-Andre Clevert, head of the Interdisciplinary Ultrasound Centre, Department of Radiology, University of Munich-Grosshadern Campus.

“The A20 gives us the opportunity for super resolution,” he said. “Five hundred frames a second means a very, very high resolution, and a lot of dynamic information, additional information for the tumour which doesn’t exist or can be missed in conventional contrast examination.”

New diagnostic pathways could become possible for different patient cohorts, he added. For kidney transplant patients, it was now possible to show a “tiny kidney infarction not clearly visible by a contrast enhanced ultrasound examination”.

For liver patients, the need for additional imaging, could potentially now be avoided, he added. “Around 30 per cent of my liver examination patients need to have CT or MRI, and further contrast enhanced ultrasound,” said Professor Clevert. “There might be an option for a shortcut, to start with super resolution before going to MRI or CT – to save both time and money.”

‘A huge amount of data’: A new perspective for doctors

The new ultrasound system uses an acoustic intelligence technology platform, combined with Mindray’s next-generation transducers to improve acoustic focusing, and support precise diagnosis.  This helps healthcare professionals to visualise often unseen details.

Professor Clevert said that the Resona A20’s option for super resolution meant “more frames in a shorter time, with additional information like dynamic flow direction”, in addition to providing results of image analysis on the same system, preventing the need to transfer information to external computers.

“You have the option to see very tiny vessels which are not normally visible,” he said. “You can see the flow direction, you get information regarding time of arrival, so how fast the contrast has arrived. It’s not only super resolution, we have vascular information, dynamic information.”

He described the potential for a “very big power insight”. “If you can acquire 500 frames in a second, and you can store 30 seconds, this means you have around 15,000 frames. This is a huge amount of data.”

 

News

Menstrual health innovation shortlist revealed

Published

on

We are thrilled to announce the shortlist for the Menstrual Health Innovation Award at the third annual FemTech World Awards.

This award, sponsored by Premom exists to celebrate the trailblazers redefining what menstrual health means in the modern world.

It recognises breakthrough products, services, and initiatives that are pushing boundaries in technology, product design, education, accessibility, and destigmatisation.

Premom’s innovative ovulation prediction app combines a digital ovulation test reader, intelligent fertility charting, and customised cycle insights to simplify the path to motherhood.

Sister company easy@Home was the first brand in the USA to offer personalised testing solutions and devices, and has become the largest volume seller of ovulation tests in the country.

Premom’s sponsorship of this award reflects a shared commitment to empowering women with better tools, better knowledge and better outcomes across every stage of their reproductive health journey.

This year’s shortlist is a testament to the remarkable breadth of innovation happening across the femtech landscape, from wearable bioelectronics to mission-driven apps reaching underserved communities across the globe.

Congratulations to the finalist and thank you to everyone who nominated.

Menstrual Health Innovation Shortlist

Founded by healthcare designer Kateřina Rydlová, who wanted to manage her own period pain without relying on medication, Body Moody has developed a discreet, wearable heated bodysuit that delivers targeted warmth to the abdomen and back – quietly, under everyday clothing.

Made from soft viscose, controlled via a companion app, and built for 200+ washes and over five years of use, the bodysuit is as practical as it is pioneering.

Their borrow-then-buy model lowers the barrier to entry and early customer feedback speaks for itself, with users reporting that they have gone from averaging multiple painkillers per cycle to needing none at all.

Eshe is a women’s health ecosystem built for a part of the world that femtech has long overlooked.

Rooted in Sub-Saharan Africa, where 69 per cent of global maternal deaths occur, 65 per cent of women and girls in Kenya cannot afford sanitary pads, and over 60 per cent of women lack access to preventive healthcare, Eshe was created to meet women where they are.

The Eshe app offers daily menstrual cycle and fertility tracking, pregnancy monitoring, mental wellbeing check-ins, in-app consultations with qualified doctors, and health education content, all in one place.

By identifying irregular cycles, missed periods and mental health changes, the platform nudges users toward timely action rather than emergency intervention.

Polycystic ovary syndrome (PCOS) affects almost one in five women, making it the leading cause of infertility and a significant risk factor for conditions spanning obesity, cardiovascular disease, cancer, and cognitive decline.

Despite this staggering burden, there has not been a new treatment option in seven decades – until now.

LoOoP is a bioelectronic device paired with the MyLoOoP companion app, designed to address both the metabolic and menstrual symptoms of PCOS with the ultimate ambition of avoiding, delaying, or reducing its long-term complications.

The MyLoOoP digital platform goes further still, combining evidence-backed content, clinically validated journaling tools, a validated phenotyping algorithm, and an inclusive community – closing the persistent gaps in PCOS diagnosis, information and care.

What happens next

The shortlist will be judge by a Premom representative who will announce the winner at a virtual event on June 19.

The winner will receive a trophy and be interviewed by a Femtech World journalist.

Continue Reading

Mental health

Dr-Julian helps deliver breakthrough mental health support for Black and ethnically minoritised mothers

Published

on

A groundbreaking digital perinatal mental health pilot for Black and ethnically minoritised women has helped women access support faster, complete therapy at higher rates, and recover more successfully than national averages.

The partnership between digital tech company Dr-Julian and The Essential Baby Company Ltd within a new model of mental health care named haPPIE SHE Cares  – who offer personalised support for women sharing their healthcare experiences, showed results well above NHS benchmarks for Black and ethnically minoritised women.

The pilot was created to help women who are less likely to use traditional mental health services during pregnancy and in the first year after giving birth.

By combining trusted community referrals, culturally aware support, and fast access to therapy through Dr-Julian’s online and virtual care platform, the programme delivered standout results.

Every woman who joined the pilot started therapy, 90 per cent completed treatment, and 74 per cent recovered; well above the NHS benchmark of around 52 per cent.

Women referred through community organisations accessed support in just one day on average, compared with around 21 days through many standard services.

Even the programme’s regular referral route reduced waits to 13 days.

The findings come as NHS leaders continue to focus on maternity inequalities and unequal access to mental health care.

Black and ethnically minoritised women can face barriers including stigma, language needs, lack of trust in services, childcare pressures, and difficulty navigating complex systems.

The haPPIE SHE Cares model was designed to break down those barriers by working with trusted community groups, offering culturally informed support, and where possible matching women with therapists who understood their background or language.

Gemma Poole for The Essential Baby Company said: “Too many women who need help feel unseen, unheard or unable to get support when they need it most.

“This project shows that when services are built around trust, culture and community, women engage, recover and thrive.

“This early success could provide a blueprint for reducing inequalities in maternal mental health care across the UK. Behind every statistic is a mother who felt supported, a family that benefited and a woman who found her voice.

“Mental healthcare must work for every community. This partnership shows that when high-quality therapy is combined with culturally responsive support, outcomes improve and women get help faster.

We are proud to have provided the therapists, virtual care systems and digital pathways behind this programme. We believe this model could help NHS organisations nationwide cut waiting times and improve recovery rates.”

Women who took part described the programme as life-changing, saying it reduced isolation, gave them confidence speaking with healthcare professionals, and made them more willing to seek help.

With growing pressure on maternity and mental health services, leaders behind the project say the pilot offers a practical solution that improves care while helping cut long waiting lists.

Plans are now being explored to expand the model through training, regional partnerships, and future funding.

Continue Reading

Diagnosis

Women unaware of gynaecological cancers

Published

on

Only one per cent of women can name all five gynaecological cancers, new research suggests, as 21 women in the UK die every day of the diseases.

The report also found that 31 per cent of women have put off or avoided seeking medical advice for gynaecological symptoms.

It also found that 43 per cent of women invited for cervical screening said barriers had put them off attending, while 18 per cent of respondents aged 25 to 34 who had been invited had never attended.

The five main gynaecological cancers are womb, also called uterine, ovarian, cervical, vulval and vaginal cancer.

The Lady Garden Foundation said that, while progress has been made since the UK government’s 2022 Women’s Health Strategy aimed to improve gynaecological cancer care, significant challenges remain.

John Butler, medical director and trustee at the Lady Garden Foundation, said: “The fact that only one per cent of the population can name the diseases that directly affect half of us underscores a significant awareness gap, impacting individuals’ ability to recognise vital signs and symptoms or seek timely medical help.

“Addressing this isn’t just about awareness; it’s a critical public health priority. Our collective efforts are essential to ensure the latest commitments announced by this government translate into tangible change that saves lives.”

The report said key reasons for delaying medical advice included difficulty making appointments, embarrassment and, for cervical screening, fear of pain or previous bad experiences.

Women also reported challenges within healthcare interactions, including feeling “not taken seriously”, “dismissed” or “not believed” when seeking gynaecological advice.

Jenny Halpern Prince, chief executive and charity co-founder, said: “We frequently hear reports of women feeling ‘not taken seriously,’ ‘dismissed,’ or ‘not believed’ when seeking gynaecological advice.

“These experiences highlight crucial areas where we can improve patient support and trust within our healthcare system, ensuring women receive the empathetic and effective care they need.”

The Lady Garden Foundation said it aims to increase awareness of both the charity and the five gynaecological cancers.

It also aims to serve as a primary entry point for reliable, stigma-free information, helping people understand their bodies, recognise symptoms and overcome barriers to accessing care.

Its Silent No More Garden was unveiled at the RHS Chelsea Flower Show 2026. Designed by Darren Hawkes, the garden serves as a national call to action, using five sculptures to spark conversations, break long-standing taboos and encourage open dialogue about symptoms and preventative care.

Butler said: “Continued focus and collaborative action are essential to progress.

“The ongoing commitment from the government, alongside societal efforts to break down taboos surrounding gynaecological health, are crucial.

“The Lady Garden Foundation is dedicated to being a beacon of information and support, empowering women with the knowledge they need. We urge everyone to learn the signs, speak up, and help us save lives.”

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.